Krystal Biotech, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-81.1% vs price
Base Case (Median)
-74.1% vs price
Bull Case (75th pct.)
-47.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $55.07 | -83.6% | High (40%) |
| PE Comparable | $177.59 | -47.1% | Medium (25%) |
| Growth Trajectory DCF | $574.83 | 71.2% | Medium (20%) |
| Graham Number | $86.98 | -74.1% | Medium (40%) |
| EV/EBITDA | $67.72 | -79.8% | Medium (20%) |
| EV/FCF | $178.12 | -46.9% | Medium (20%) |
| Earnings Power Value | $58.92 | -82.4% | Medium (50%) |
Based on 7 out of 8 methods, KRYS appears overvalued at the current price of $335.73. The base case fair value of $86.98 implies 74.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.